Patents by Inventor Ngan Nguyen

Ngan Nguyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EPHA2 ANTIBODIES
    Publication number: 20250051464
    Abstract: Provided herein are EphA2 antibodies. These EphA2 antibodies bind preferentially to tumor tissue than normal tissue and bind to EphA2. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
    Type: Application
    Filed: October 25, 2024
    Publication date: February 13, 2025
    Inventors: Alexander Scholz, Nikhil Vad, Michael Samuel Weiss, Anne Ye, Danhui Zhang, Iraz T. Aydin, Maryam M. Bhatti, Sean Carroll, Jessica Finn, Shuning Gai, Shaun M. Lippow, Amy Manning-Bog, Philippe Marguet, Ngan Nguyen Atkins
  • EPHA2 antibodies
    Patent number: 12162945
    Abstract: Provided herein are EphA2 antibodies. These EphA2 antibodies bind preferentially to tumor tissue than normal tissue and bind to EphA2. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: December 10, 2024
    Assignee: Immunome, Inc.
    Inventors: Alexander Scholz, Nikhil Vad, Michael Samuel Weiss, Anne Ye, Danhui Zhang, Iraz T. Aydin, Maryam M. Bhatti, Sean Carroll, Jessica Finn, Shuning Gai, Shaun M. Lippow, Amy Manning-Bog, Philippe Marguet, Ngan Nguyen Atkins
  • ANTIBODIES TO CORONAVIRUS SARS-COV-2
    Publication number: 20240327505
    Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.
    Type: Application
    Filed: October 20, 2022
    Publication date: October 3, 2024
    Applicants: University of Vermont and State Agricultural College, Atreca, Inc.
    Inventors: Jason Botten, Katherine L. Williams, Ngan Nguyen Atkins, Annalis Whitaker
  • ANTIBODIES TO SARS-COV-2
    Publication number: 20240301038
    Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.
    Type: Application
    Filed: March 24, 2022
    Publication date: September 12, 2024
    Applicants: Atreca, Inc., University of Vermont and State Agricultural College
    Inventors: Katherine L. Williams, Daniel Eric Emerling, Shaun M. Lippow, Ngan Nguyen Atkins, Jason Botten, Annalis Whitaker
  • ANTIBODIES TO CORONAVIRUS SARS-COV-2
    Publication number: 20240025971
    Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.
    Type: Application
    Filed: October 22, 2021
    Publication date: January 25, 2024
    Inventors: Katherine L. WILLIAMS, Daniel Eric EMERLING, Shaun M. LIPPOW, Ngan Nguyen ATKINS
  • ISTHMIN 1 FOR TREATMENT OF LUNG INFLAMMATION
    Publication number: 20230190868
    Abstract: Provided herein are polypeptides including an amino acid sequence having at least 70% sequence identity with an Isthmin 1 (ISM1) protein or a GRP78-activating fragment thereof, as well as expressible nucleic acids encoding said polypeptides. Uses of such agents, as well as methods for inducing apoptosis in alveolar macrophages and/or for treating, ameliorating, or preventing inflammation or lung disease such as chronic obstructive pulmonary disease (COPD), emphysema, asthma, acute lung injury (ALI), lung fibrosis, and/or acute respiratory distress syndrome.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 22, 2023
    Inventors: Ruowen GE, Yin Weng Terence LAM, Tran Bich Ngan NGUYEN, Wai-Shiu Fred WONG
  • Pyrazole compounds as modulators of FSHR and uses thereof
    Patent number: 11365199
    Abstract: The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: June 21, 2022
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Marianne Donnelly, Ngan Nguyen, Xuliang Jiang
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10413562
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: September 17, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF
    Publication number: 20180354965
    Abstract: The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Application
    Filed: August 22, 2018
    Publication date: December 13, 2018
    Inventors: Henry YU, Marianne DONNELLY, Ngan NGUYEN, Xuliang JIANG
  • Imidazole compounds as modulators of FSHR and uses thereof
    Patent number: 10138233
    Abstract: The present invention relates to imidazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 27, 2018
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Thomas E. Richardson, Marianne Donnelly, Ngan Nguyen, Xuliang Jiang
  • Pyrazole compounds as modulators of FSHR and uses thereof
    Patent number: 10081637
    Abstract: The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: September 25, 2018
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Marianne Donnelly, Ngan Nguyen, Xuliang Jiang
  • COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
    Publication number: 20180243324
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Inventors: Brian L. HODOUS, Lesley LIU-BUJALSKI, Reinaldo JONES, Donald BANKSTON, Theresa L. JOHNSON, Igor MOCHALKIN, Ngan NGUYEN, Hui QIU, Andreas GOUTOPOULOS, Nadia BRUGGER
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 10030013
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 24, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones, Annie Cho Won, Ngan Nguyen, Theresa L. Johnson, Lizbeth Celeste Deselm, Kausik Panda
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10016448
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
    Patent number: 10005784
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: June 26, 2018
    Assignee: Merck Patent GmbH
    Inventors: Lesley Liu-Bujalski, Ngan Nguyen, Hui Qiu, Reinaldo Jones, Igor Mochalkin, Richard D. Caldwell
  • HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
    Publication number: 20180002327
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 4, 2018
    Inventors: Catherine JORAND-LEBRUN, Reinaldo JONES, Annie Cho WON, Ngan NGUYEN, Theresa L. JOHNSON, Lizbeth Celeste DESELM, Kausik PANDA
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 9790221
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: October 17, 2017
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones, Annie Cho Won, Ngan Nguyen, Theresa L. Johnson, Lizbeth Celeste Deselm, Kausik Panda
  • Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
    Patent number: 9738648
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: August 22, 2017
    Assignee: Merck Patent GmbH
    Inventors: Lesley Liu-Bujalski, Ngan Nguyen, Hui Qiu, Reinaldo Jones, Igor Mochalkin, Richard D. Caldwell
  • PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20170226113
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazene compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 10, 2017
    Inventors: Lesley LIU-BUJALSKI, Ngan NGUYEN, Hui QIU, Reinaldo JONES, Igor MOCHALKIN, Richard D. CALDWELL
  • COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
    Publication number: 20170136048
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Inventors: Brian L. HODOUS, Lesley LIU-BUJALSKI, Reinaldo JONES, Donald BANKSTON, Theresa L. JOHNSON, Igor MOCHALKIN, Ngan NGUYEN, Hui QIU, Andreas GOUTOPOULOS, Nadia BRUGGER